Great Lakes Advisors LLC Has $5.36 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Great Lakes Advisors LLC reduced its holdings in Supernus Pharmaceuticals by 3.5%, owning approximately 0.29% of the company valued at around $5.36 million after the sale of 5,977 shares.
• Insider selling was significant, with SVP Frank Mottola and CFO Timothy C. Dec selling a combined total of 25,780 shares, representing drastic decreases in their ownership percentages.
• Wall Street analysts have a mixed outlook on Supernus Pharmaceuticals, with target prices varying between $36.00 and $46.00, indicating both a potential for growth and a cautious stance.

Great Lakes Advisors LLC lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 163,580 shares of the specialty pharmaceutical company's stock after selling 5,977 shares during the quarter. Great Lakes Advisors LLC owned 0.29% of Supernus Pharmaceuticals worth $5,357,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. Raiffeisen Bank International AG acquired a new position in Supernus Pharmaceuticals in the fourth quarter valued at $25,000. Financial Management Professionals Inc. acquired a new position in Supernus Pharmaceuticals in the first quarter valued at approximately $30,000. Versant Capital Management Inc boosted its stake in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 1,109 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Supernus Pharmaceuticals in the first quarter valued at approximately $41,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $42,000.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SUPN. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Piper Sandler upped their price target on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $43.00.

Supernus Pharmaceuticals Stock Down 1.8%

SUPN stock traded down $0.83 during mid-day trading on Monday, reaching $44.63. 142,856 shares of the stock traded hands, compared to its average volume of 634,263. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $46.78. The business has a 50-day moving average of $39.42 and a two-hundred day moving average of $34.62. The firm has a market capitalization of $2.50 billion, a PE ratio of 38.78 and a beta of 0.79.

Insider Activity at Supernus Pharmaceuticals

In other news, Director Bethany Sensenig sold 5,369 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.51, for a total transaction of $623,140.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company's stock, valued at $689,726.96. This represents a 47.46% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 241,506 shares of company stock valued at $10,466,794. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.